Institute for Government · Institute for Government

How can the government deliver its “prevention first” approach to healthcare?

·1 hr·5 clips

Dr. Joe Bibby exposes a 20-year gap in healthy life expectancy across the UK, driven by deprivation, not the NHS.

This Institute for Government event examines the practical challenges of shifting the UK's healthcare system toward a "prevention first" approach. Host Nick Davies moderates a panel featuring Dr. Joe Bibby from the Health Foundation, Rob Thomas of Novartis Pharmaceuticals UK, Nick Mead from Genetic Alliance UK, and Stuart Hodnot from the Institute for Government. Dr. Joe Bibby highlights a 16-year life expectancy gap and a 20-year healthy life expectancy gap across UK postcodes, attributing these inequalities primarily to deprivation and socioeconomic status. He argues for investment in mental health, pain management, the public health grant, early years support, and the NHS's role as a major employer and anchor institution. Rob Thomas notes that 40% of the UK population lives with a long-term condition, with 25% experiencing multi-morbidity, and cites a report labeling the UK as "the sick man of Europe" for lagging in health outcomes. He emphasizes secondary prevention, like screening high-risk populations, and states the UK screens newborns for fewer than half the conditions many European nations do. Nick Mead states that over 70% of the roughly 7,000 rare conditions have a genetic cause, with only about 5% having a treatment that can change the condition's course. He explains the UK's newborn heel-prick test screens for only nine conditions, while countries like Austria and Italy screen for over thirty. Stuart Hodnot identifies that political, structural, financial, and cultural incentives in government consistently push against long-term preventative spending, using the Sure Start program as an example of a initiative that required high-level political support to overcome Treasury objections. A surprising claim is that medical knowledge now doubles every 70 days, compared to an estimated 50-year cycle in 1950. The panel notes the UK's National Screening Committee has not added a new condition to the newborn screening list since 2017, and the country ranks ninth for the availability of new medicines. An interesting insight is the proposal to create a separate spending stream for prevention, similar to capital spending, to protect investments with long-term benefits from short-term budget pressures. The discussion reveals a significant barrier to pooled budgets is that service silos create incentives to push costs onto other sectors, like hospitals delaying patient discharges to avoid local authority care costs. The tone is analytical and policy-focused, grounded in research and data from the panelists' respective organizations. The style is a structured panel discussion, moving from opening remarks to moderator questions and finally audience Q&A. This episode would appeal to policymakers, public health professionals, and anyone interested in the structural and financial mechanics of healthcare reform. Listeners seeking a high-level debate on specific medical treatments or personal health narratives might find it less engaging.

As heard by us

A serious look at how prevention becomes something the NHS can actually deliver.

This piece treats prevention as a delivery problem, not a slogan. It follows how the UK might shift from sickness toward prevention, with a focus on incentives, local accountability, spending protection, and the tension between long-term public value and short-term budget…

Read the full review in PlayNext →

Why you'd press play

Hear the case for a prevention-led NHS, and how the system might be made to follow through.

Read the full recommendation in PlayNext →

Listen to the show on

Apple Podcasts Spotify

Play clips from this episode More from Institute for Government